NEW YORK (GenomeWeb News) - MDS has signed a definitive agreement to buy Molecular Devices, a maker of high-content screening, cellular analysis, and biochemical testing tools, for $615 million in cash, the companies said today.
The agreement calls for MDS to pay $35.50 per share for all of Molecular Devices’ common stock. The boards of both companies have approved the transaction.
MDS shares closed at $23.88 on Friday.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.